A 15,000-person Swedish study found people with bipolar disorder taking semaglutide had a 21% lower risk of psychiatric hospitalization — an intriguing signal, but not proof, and not seen with every GLP-1 drug.
Del-desiran, the lead muscle-disease therapy Novartis bought with Avidity for $12 billion, missed its main goal in myotonic dystrophy — sending the stock to its worst day since 2020.
A new American Cancer Society–WHO analysis projects annual cancer diagnoses rising from 21 million to 34 million by 2050, driven mostly by aging and population growth — with the heaviest burden falling on poorer countries.
A 132,000-person Danish study found people who began statins within a year of a type 2 diabetes diagnosis had a 15% lower 10-year dementia risk — though it can’t prove the drugs are the cause.
BrainChild Bio is betting that delivering engineered immune cells directly into the brain — not through the bloodstream — can finally reach some of the deadliest childhood cancers.
After the drug lowered inflammation but not heart attacks in a big Phase 3, a monitoring committee judged two follow-on trials unlikely to succeed — a setback for the “inflammation causes heart disease” strategy.
The deal brings GSK a first-in-class “antibody-targeted therapy conjugate” that hits EGFR and KRAS at once — a design meant to aim a potent KRAS blocker straight at tumors.
Hospital pharmacists and industry are jointly pushing to extend medicine barcodes down to the individual dose — a change they say could sharply cut bedside medication errors.
AtomVie has opened what it calls North America’s largest single-site radiopharmaceutical manufacturing facility — a bet on the fast-growing field of radioactive targeted therapies.
Aptar Pharma is joining Aceso Therapeutics to develop ACT-101 — an inhalable oligonucleotide that works at the RNA level, before the faulty CF protein is even built.
The amino acid, sold as a focus-and-alertness supplement, was linked to reduced life expectancy in men in a large genetic analysis — but researchers stress it doesn’t show supplements shorten life.
Medicines Discovery Catapult is funding Flip Therapeutics and Nascent Therapeutics — one reprogramming immune cells, the other restoring aging cells’ power plants.